Every public signal F4 has attached to this firm, with sources and cross-entity links.
Press
Nordic Life Science publishes in-depth profile interview with HealthCap co-founder Björn Odlander on the firm's 30-year approach to life science investing, its portfolio track record, and Europe's capital gap.
Björn Odlander interviewed on HealthCap's 30-year journey
HealthCap joined the SEK 347 million Series B second closing of Gesynta Pharma, alongside Hadean Growth Fund and led by Innovestor Life Science. HealthCap partner Kristina Ekberg appointed to the board.
Novo Holdings and the Danish Export and Investment Fund (EIFO) invested €48 million in HealthCap IX, HealthCap's ninth fund, to strengthen the Nordic life sciences ecosystem.
Novo Holdings and EIFO invest €48M in HealthCap IX